MAZE THERAPEUTICS, INC.
MAZELoading price...
Overview
Previous Close45.06
Open46.29
Ask59.20
Bid36.44
Day's Range45.56 - 51.36
52 Week Range6.71 - 51.36
PE Ratio(TTM)--
Market Cap2.46B
Volume1.28M
Avg. Volume465.05k
12 Months Earnings-126.13M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Revenue | 0.00 | 167.50M | 0.00 | 0.00 |
| Operating Expenses | 134.57M | 109.91M | 98.55M | 111.03M |
| Profit after Tax (Net Income) | -126.13M | 52.23M | -100.42M | -114.94M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: South San Francisco, United States
Website: https://www.mazetx.com
CEO & Director: Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
Employees: 125
About Company:
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.